A Phase II Study of Evaluating Recombinant Human Anti-EGFR Monoclonal Antibody (SCT200) and Standard Chemotherapy for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Latest Information Update: 05 May 2022
At a glance
- Drugs SCT 200 (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 26 May 2020 Planned primary completion date changed from 31 Mar 2020 to 30 Jun 2020.
- 03 Feb 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 18 Mar 2019 New trial record